Talk:Mallinckrodt

From Wikipedia, the free encyclopedia
Jump to: navigation, search
WikiProject Pharmacology (Rated Stub-class)
WikiProject icon This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.
Stub-Class article Stub  This article has been rated as Stub-Class on the project's quality scale.
 ???  This article has not yet received a rating on the project's importance scale.
 


I am proposing the following article revision. Details of the revisions and additions are found at the bottom of this entry, under the proposed revised article. However, before I make the edits to the actual article itself, I was advised by Wikipedia editor User:Huon to make my recommendations to the Talk page first. In addition, I have incorporated the editorial changes recommended to my original submission, including replacing blogs as sources, removing the sentence that had the SEC as a source (not considered neutral), changing language to clarify cocaine statement (editor was skeptical) and adding Wikilinks per editor's recommendation. In addition to the recommended improvements to my draft, the editor also noted that my article includes an "impressive selection of reliable, truly independent sources that may well serve to improve our coverage of the company, especially its early history and the various acquisitions."

REVISED ARTICLE:

Mallinckrodt, based in St. Louis, Missouri, is the pharmaceuticals business of Covidien, a global healthcare products company based in Dublin, Ireland that manufactures, distributes and services medical devices, pharmaceuticals and medical supplies. [1]

Mallinckrodt manufactures and distributes products used in diagnostic procedures and in the treatment of pain and related conditions. This includes the development, manufacture and distribution of specialty pharmaceuticals, active pharmaceutical ingredients, contrast products and radiopharmaceuticals. The company employs 5,500 at 47 locations around the world. Net sales were $2 billion in 2011. [2]

Separation from Covidien[edit]

In 2011, Covidien announced plans to spin off its pharmaceuticals business into a standalone public company. [3]

History[edit]

Early History[edit]

In 1867, the Mallinckrodt brothers, Gustav, Otto and Edward, founded G. Mallinckrodt & Co. in St. Louis, Missouri.[4] Mallinckrodt Chemical Works was incorporated 15 years later. By 1898, the company had established itself as a pharmaceuticals supplier and in 1913 became the first to introduce barium sulfate as a contrast media for x-rays. The Mallinckrodt General Clinical Research Center received contributions from Edward C. Mallinckrodt, Jr., who headed the firm in the 1940s.

Recent History[edit]

  • 1981 – Mallinckrodt is listed among Fortune 500 companies [5]
  • 1982 – Avon Products, Inc. acquires Mallinckrodt
  • 1986 – International Minerals and Chemical Corporation (IMCERA Group Inc.) acquires Mallinckrodt from Avon
  • 1995 – Mallinckrodt establishes generic pharmaceuticals business
  • 1996 – Mallinckrodt Inc. acquires maker of urology imaging systems and injectors, Liebel-Flarsheim Co. [6]
  • 2000 – Tyco International acquires Mallinckrodt [7]
  • 2007 – Tyco Healthcare spins off and becomes Covidien, an independent company [8]
  • 2011 – Covidien closes plant in Chesterfield, UK which makes para-aminophenol, with the loss of 64 jobs.
  • 2011 – Covidien announces plans to spin off Mallinckrodt Pharmaceuticals as a standalone public company [9]
  • 2012 – Mallinckrodt announces acquisition of CNS Therapeutics for $100 million [10]

Market[edit]

Mallinckrodt markets its products to major wholesalers and retail drug store chains. Imaging products are marketed primarily to physicians, technologists and hospitals, imaging centers, cardiology clinics and radiopharmacies.[2]

Products[edit]

Mallinckrodt is the largest U.S. supplier, by prescription, of opioid pain medications and the largest U.S. supplier of the medical isotope technetium-99m. The company is among the top 10 generic pharmaceuticals manufacturers in the United States.[11] The company is also the largest producer of bulk acetominophen. [12]

Ingredient Sourcing[edit]

Mallinckrodt sources ingredients nationally and outside of the U.S. The company legally sources cocaine from the Stepan Company plant in Maywood, New Jersey. Mallinckrodt is also one of the U.S. importers of opium from India. [13] Until 2010, the National Institute on Drug Abuse at the University of Mississippi supplied Mallinckrodt with marijuana to produce a generic version of Marinol. [14]

References[edit]


Here are the detailed explanations of the revisions that I made from the original article to the new proposed article:
REVISION 1)
MOVED SENTENCE TO THE HISTORY SECTION WHERE IT MADE MORE SENSE. IT WAS PREVIOUSLY AT THE END OF THE ARTICLE: 2011 – Covidien closes plant in Chesterfield, UK which makes para-aminophenol, with the loss of 64 jobs.

REVISION 2)
REPLACED THE FOLLOWING SENTENCE:
Mallinckrodt is the sole legal source for cocaine in the United States, which it receives from a Stepan Company plant in Maywood, New Jersey (in relation to the soft drink Coca-Cola) and is the only firm in the U.S. licensed to import coca leaves. Federal restrictions also bar the importation of drugs, such as Esterom, manufactured from cocaine, which therefore requires that manufacturers use this supplier. (Source: http://www.secinfo.com/dv22g.63b.htm)
EDITED BECAUSE OF FACTUAL INACCURACIES, INCLUDING:
1. Mallinckrodt is not the sole company to import cocaine to the United States. The source that states this is from 1988, and out of date. Other companies include Johnson Matthey, Sigma Aldrich, Cody Laboratories, Siegfried USA, and several others. Information on other companies that plan to import cocaine into the US are found on the DEA website. (Sources: http://www.deadiversion.usdoj.gov/fed_regs/manufact/app/2006/fr120116.htm; http://www.deadiversion.usdoj.gov/fed_regs/manufact/reg/2006/fr082210.htm; http://www.deadiversion.usdoj.gov/fed_regs/imprt/app/2009/fr09082.htm)
2. Mallinckrodt is not connected to Coca-Cola, so the reference is irrelevant to the article.
REVISION:
Mallinckrodt sources ingredients nationally and outside of the U.S. The company legally sources cocaine from the Stepan Company plant in Maywood, New Jersey. Mallinckrodt is also one of the U.S. importers of opium from India. (Source: http://www.senliscouncil.net/documents/feasibility_study_conclusions_and_recommendations)

REVISION 3)
REVISED THE FOLLOWING SENTENCE:
The most famous federally approved cannabis grower, Dr. Mahmoud El Sohly, has also testified he has begun legally selling THC extracted from his Mississippi marijuana farm to the drug company Mallinckrodt. (No Source cited.)
REVISED BECAUSE THE REFERENCE IS OUTDATED, FACTUALLY INACCURATE, AND DOES NOT CITE A SOURCE:
Dr. El Sohly worked at the university where the THC was purchased, but the original article made it sound as though the purchase was from him, not the university. Further explanation: Mallinckrodt purchased an extract derived from marijuana grown by the National Institute on Drug Abuse (http://en.wikipedia.org/wiki/National_Institute_on_Drug_Abuse) through the University of Mississippi (http://en.wikipedia.org/wiki/University_of_Mississippi), but discontinued purchasing it in 2010.
REVISION:
Until 2010, the National Institute on Drug Abuse at the University of Mississippi supplied Mallinckrodt with marijuana to produce a generic version of Marinol. (http://www.nytimes.com/2010/01/19/health/policy/19marijuana.html?_r=0)

REVISION 4)
Enhanced references by citing numerous Wiki links and external links to news and government sources.

REVISION 5)
Added detailed history and product information.
Thank you for your consideration.

--Rkhaarma (talk) 15:17, 8 April 2013 (UTC)